- PR Newswire•7 hours ago
HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the successful acquisition of the global rights to the Cold-EEZE® brand cold remedy line from ProPhase Labs, Inc. The transaction provides Mylan all assets and rights relating to the Cold-EEZE® brand, including all U.S. businesses and U.S. and international trademarks. The Cold-EEZE® family of brands includes leading over-the-counter (OTC) cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts® and oral liquid dose forms in the U.S.
- Investopedia•8 hours ago
The benchmark S&P 500 edged up on Wednesday as the stronger energy sector and soaring shares of Vertex Pharmaceuticals offset declines in financial shares and investors began looking ahead to first-quarter ...
- TheStreet.com•9 hours ago
The company's shares were falling again on Wednesday, this time on the news that its initial application for an anti-asthma generic had been rejected by the FDA.
MYL : Summary for Mylan N.V. - Yahoo Finance
Mylan N.V. (MYL)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
|Bid||40.26 x 200|
|Ask||40.35 x 1000|
|Day's Range||40.13 - 41.89|
|52 Week Range||33.60 - 50.40|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||43.86|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|